Wespac Advisors, LLC Amgen Inc Transaction History

Wespac Advisors, LLC

$168 Million
Q1 2024

A detailed history of Wespac Advisors, LLC transactions in Amgen Inc stock. As of the latest transaction made, Wespac Advisors, LLC holds 4,437 shares of AMGN stock, worth $1.38 Million. This represents 0.75% of its overall portfolio holdings.

Number of Shares

4,437

Previous 4,088 8.54%

Holding current value

$1.38 Million

Previous $1.18 Million 7.14%

% of portfolio

0.75%

Previous 0.83%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 24, 2024	BUY	$268.87 - $324.56 $93,835 - $113,271	349 Added 8.54%	4,437 $1.26 Million
Q4 2023 Jan 25, 2024	BUY	$255.7 - $288.46 $1.05 Million - $1.18 Million	4,088 New	4,088 $1.18 Million
Q1 2020 Apr 22, 2020	SELL	$182.24 - $241.7 $535,967 - $710,839	-2,941 Closed	0 $0
Q4 2019 Feb 07, 2020	SELL	$189.21 - $243.2 $69,440 - $89,254	-367 Reduced 11.09%	2,941 $709,000
Q3 2019 Oct 29, 2019	BUY	$174.11 - $208.62 $575,955 - $690,114	3,308 New	3,308 $640,000

Q2 2019 Jul 23, 2019	SELL	$166.7 - $195.41 $2.12 Million - $2.49 Million	-12,724 Closed	0 $0
Q1 2019 Apr 19, 2019	BUY	$180.87 - $203.88 $4,160 - $4,689	23 Added 0.18%	12,724 $2.39 Million
Q4 2018 Jan 31, 2019	SELL	$178.4 - $208.25 $138,438 - $161,602	-776 Reduced 5.76%	12,701 $2.47 Million
Q3 2018 Nov 02, 2018	BUY	$185.29 - $208.89 $837,881 - $944,600	4,522 Added 50.5%	13,477 $2.79 Million
Q2 2018 Aug 08, 2018	SELL	$166.05 - $186.51 $690,103 - $775,135	-4,156 Reduced 31.7%	8,955 $1.65 Million
Q1 2018 May 08, 2018	BUY	$169.43 - $198.0 $220,767 - $257,994	1,303 Added 11.03%	13,111 $2.24 Million
Q4 2017 Jan 30, 2018	BUY	$168.79 - $188.59 $1.99 Million - $2.23 Million	11,808	11,808 $2.05 Million

Others Institutions Holding AMGN

# of Institutions

2,932

Shares Held

401M

Call Options Held

6.59M

Put Options Held

6.6M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $166B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wespac Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wespac Advisors, LLC with notifications on news.

Account

Wespac Advisors, LLC Amgen Inc Transaction History